BioLife Solutions, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BioLife Solutions, Inc. (BLFS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $47.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $47.00K, a 76.50% decline year-over-year.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.80M.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $200.00K, a 60.00% decline year-over-year.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $200.00K.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $91.82K, a 78.97% increase from fiscal 2016.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $51.30K, a 59.70% decline from fiscal 2015.
- BioLife Solutions, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $127.31K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.00K 10-Q · filed 2026-08-06 | $1.90M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-06 | $400.00K derived: sum of 2 quarters · filed 2026-08-06 | $200.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-06 | $200.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.10M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $600.00K 10-Q · filed 2024-08-09 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $0.00 derived: sum of 2 quarters · filed 2018-03-09 | $21.10K derived: sum of 3 quarters · filed 2018-03-09 | $91.82K 10-K · filed 2018-03-09 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $21.10K derived: sum of 2 quarters · filed 2017-11-09 | $91.82K 10-Q · filed 2017-11-09 | $91.82K derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-06-30 | $21.10K 10-Q · filed 2017-08-11 | $91.82K 10-Q · filed 2017-08-11 | $91.82K derived: sum of 3 quarters · filed 2018-03-09 | $97.45K derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-03-31 | $70.71K 10-Q · filed 2017-05-12 | $70.71K derived: sum of 2 quarters · filed 2018-03-09 | $76.35K derived: sum of 3 quarters · filed 2018-03-09 | $117.76K derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $5.63K derived: sum of 2 quarters · filed 2018-03-09 | $47.05K derived: sum of 3 quarters · filed 2018-03-09 | $51.30K 10-K · filed 2018-03-09 |
| 2016-09-30 | $5.63K 10-Q · filed 2016-11-10 | $47.05K derived: sum of 2 quarters · filed 2016-11-10 | $51.30K 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $41.41K 10-Q · filed 2016-08-11 | $45.67K 10-Q · filed 2016-08-11 | ||
| 2016-03-31 | $4.25K 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $127.31K 10-K · filed 2017-03-15 | |||
| 2015-03-31 | $20.94K 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |